Loading...

PE anti-mouse TNF-α Antibody

Pricing & Availability
Clone
MP6-XT22 (See other available formats)
Regulatory Status
RUO
Other Names
Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF), Differentiation inducing factor (DIF), TNFSF-2, TNF-a, TNF-alpha
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
MP6-XT22_PE_TNF-a_Antibody_FC_1_100913
PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) PE (top) or rat IgG1, κ PE isotype control (bottom).
  • MP6-XT22_PE_TNF-a_Antibody_FC_1_100913
    PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) PE (top) or rat IgG1, κ PE isotype control (bottom).
  • MP6-XT22_PE_TNF-a_Antibody_FC_2_101413
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
506305 25 µg 55€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
506306 100 µg 191€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

TNF-α is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells. Many transformed cell lines also secrete TNF-α. Monomeric mouse TNF-α is a 156 amino acid protein (N-glycosylated) with a reported molecular weight of 17.5 kD. TNF-α forms multimeric complexes; stable trimers are most common in solution. A 26 kD membrane form of TNF-α has also been described. TNF-α binding to surface receptors elicits a wide array of biologic activities including: cytolysis and cytostasis of many tumor cell lines in vitro, hemorrhagic necrosis of tumors in vivo, increased fibroblast proliferation, and enhanced chemotaxis and phagocytosis in neutrophils.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse TNF-α
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA or ELISPOT Detection: The biotinylated MP6-XT22 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified 6B8 antibody (Cat. Nos. 510802 & 510804) as the capture antibody.
ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.
Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.
Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivity in vivo and in vitro(Cat. No. 506310). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9 in vivo detection5, immunofluorescence, and immunocytochemistry.
Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
  2. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20
  3. Mo X, et al. 1995. J. Virol. 69:1288.
  4. Sarawar S, et al. 1994. J. Immunol. 153:1246.
  5. Via C, et al. 2001. J. Immunol. 167:6821. (Neut)
  6. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (FC)
  7. Jacobs M, et al. 2000. Immunology 100:494. (IHC)
  8. Marinova-Mutachieva L, et al. 1997. Clin. Exp. Immunol. 107:507. (IHC)
  9. Williams RO, et al. 2000. J. Immunol. 165:7240. (IHC)
  10. Scanga CA, et al. 1999. Infect. Immun. 67:4531. (Neut)
  11. Akilov OE, et al. 2007. J. Leukoc. Biol. 2007;10.1189/jlb.0706439. (FC)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Patole PS, et al. 2005. J. Am. Soc. Nephrol. 16:3273. PubMed
  14. Wu S, et al. 2005. Neurosci Lett. 394:158. PubMed
  15. Carlson MJ, et al. 2009. Blood 113:1365. PubMed
  16. Shivakumar P, et al. 2017. JCI Insight. 2:e88747 1. PubMed
  17. Kearney CJ, et al. 2017. Cell Death Differ. 10.1038/cdd.2017.94. PubMed
Product Citations
  1. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  2. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  3. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
  4. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  5. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  6. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  7. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  8. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  9. Asrat S, et al. 2014. PLoS Pathog. 10:1004229. PubMed
  10. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  11. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  12. Mendonça-Vieira LR, et al. 2021. Viruses. 13:. PubMed
  13. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  14. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  15. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  16. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  17. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  18. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  19. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  20. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  21. Balood M, et al. 2022. Nature. 611:405. PubMed
  22. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  23. Liu L, et al. 2022. Cell Biosci. 12:193. PubMed
  24. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  25. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  26. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  27. Zander R, et al. 2022. Immunity. 55:475. PubMed
  28. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  29. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  30. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  31. Wang Y, et al. 2021. Andrologia. 53:e14239. PubMed
  32. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  33. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  34. Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed
  35. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  36. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  37. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  38. Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
  39. Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed
  40. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  41. Liu X, et al. 2020. Nature. . PubMed
  42. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  43. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  44. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  45. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  46. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  47. Murphy M, et al. 2017. Eur J Immunol. 47:880. PubMed
  48. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  49. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  50. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  51. Suzuki M, et al. 2021. Sci Adv. 7:. PubMed
  52. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  53. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  54. Chen X, et al. 2020. Andrologia. 52:e13823. PubMed
  55. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  56. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  57. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  58. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  59. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  60. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  61. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  62. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  63. Huang J, et al. 2015. Biochem Biophys Res Commun. 463: 551-556. PubMed
  64. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  65. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  66. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  67. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  68. Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed
  69. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  70. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  71. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  72. Xu S, et al. 2021. Immunity. . PubMed
  73. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  74. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  75. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  76. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  77. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  78. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  79. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  80. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  81. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  82. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  83. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  84. Stutz MD et al. 2018. Frontiers in immunology. 1.193055556 . PubMed
  85. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  86. Akilov O, et al. 2007. J Leukoc Biol. 81:1188. PubMed
  87. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  88. Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed
  89. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  90. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  91. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  92. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  93. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  94. Bennion BG, et al. 2019. J Virol. 93. PubMed
  95. Baratin M, et al. 2017. Immunity. 47:349. PubMed
  96. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  97. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  98. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  99. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  100. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  101. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  102. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  103. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  104. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  105. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  106. Liu J, et al. 2016. Cancer Res . 76: 5288 - 5301. PubMed
  107. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  108. Dahlin J, et al. 2012. J Immunol. 189:3869. PubMed
  109. Iyer RF, et al. 2022. PLoS Pathog. 18:e1010783. PubMed
  110. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  111. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  112. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  113. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  114. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  115. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  116. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  117. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  118. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  119. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
RRID
AB_315426 (BioLegend Cat. No. 506305)
AB_315426 (BioLegend Cat. No. 506306)

Antigen Details

Structure
TNF superfamily; dimer/trimer; 17.5-150 kD (Mammalian)
Bioactivity
Paracrine/endocrine mediator of inflammatory and immune functions; selectively cytotoxic for transformed cells; endothelial cell alterations; chemoattractant
Cell Sources
Activated monocytes, neutrophils, macrophages, T cells, B cells, NK cells, LAK cells
Cell Targets
Monocytes, neutrophils, macrophages, T cells, fibroblasts, endothelial cells, osteoclasts, adipocytes, astroglia, microglia
Receptors
TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-p80 Type A, p75)
Cell Type
Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.

Regulation
Processed by TACE for secretion; upregulated by interferons, IL-2, GM-CSF, substance P, bradykinin, PAF, immune complexes, and cyclooxygenase; downregulated by IL-6, TGF-β, vitamin D3, prostaglandin E2, and PAF antagonists
Gene ID
21926 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
TNF-alpha
Specificity Alt (DOES NOT SHOW ON TDS):
TNF-α
App Abbreviation (DOES NOT SHOW ON TDS):
ICFC
UniProt
View information about TNF-alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 10.14.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account